Finance

Lists
Q3 2026 earnings • released • Revenue beat +14.25%
See results
SAN:EPA
Sanofi SA
€81.33
+0.87%
(+0.70) 1D
Nov 3, 2:56:34 PM GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for SAN...
Open
€81.80
High
€82.01
Low
€81.04
Mkt. cap
98.22B
Avg. vol.
2.45M
Volume
694.15K
P/E ratio
23.39
52-wk high
€90.79
52-wk low
€69.75
EPS
€3.48
Shares outstanding
1.21B
No. of employees
75K
Open
€81.80
High
€82.01
Low
€81.04
Mkt. cap
98.22B
Avg. vol.
2.45M
Volume
694.15K
P/E ratio
23.39
52-wk high
€90.79
52-wk low
€69.75
EPS
€3.48
Shares outstanding
1.21B
No. of employees
75K
News stories
From web sources and news partners
Profile
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of the Euro Stoxx 50 stock market index. In 2023, the company was ranked 89th in the Forbes Global 2000. Sanofi engages in the research and development, manufacturing, and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. It is one of the world's largest producer of vaccines through its subsidiary Sanofi Pasteur. Wikipedia
About Sanofi SA
CEOPaul Hudson | Belén Garijo
Employees74.8K
Founded1973
HeadquartersParis, Île-de-France, France
SectorPharmaceutical industry
Websitesanofi.com
Last report
Oct 30, 2026
Fiscal period
Q3 2026
- / -
Revenue / Est. (EUR)
15.23B / 13.33B
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
12.20B
11.24B
12.30B
15.23B
Cost of goods sold
3.63B
3.06B
2.89B
3.63B
Cost of revenue
3.63B
3.06B
2.89B
3.63B
Research and development expenses
2.29B
1.75B
2.23B
1.85B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.82B
2.33B
2.49B
2.31B
Operating expense
6.84B
5.94B
6.82B
6.90B
Total operating expenses
10.46B
9.00B
9.71B
10.53B
Operating income
1.74B
2.25B
2.59B
4.70B
Other non operating income
122.00M
-40.00M
-91.00M
-
EBT including unusual items
-1.16B
2.01B
828.00M
4.22B
EBT excluding unusual items
1.70B
2.14B
2.40B
4.58B
Income tax expense
-348.00M
420.00M
451.00M
1.20B
Effective tax rate
30.13%
20.85%
54.47%
28.29%
Other operating expenses
1.19B
1.33B
1.55B
2.18B
Net income
-801.00M
1.61B
343.00M
3.02B
Net profit margin
-6.56%
14.35%
2.79%
19.83%
Earnings per share
1.53
1.88
-
-
Interest and investment income
79.00M
60.00M
64.00M
77.00M
Interest expense
-
-138.00M
-153.00M
-222.00M
Net interest expenses
79.00M
-78.00M
-89.00M
-145.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
3.49B
2.78B
3.83B
5.68B
Gain or loss from assets sale
-79.00M
-
-9.00M
9.00M
Upcoming events
AI content may include mistakes. Learn more
Google apps